PROCEPT BioRobotics (NASDAQ:PRCT) Releases Quarterly Earnings Results, Misses Estimates By $0.01 EPS

PROCEPT BioRobotics (NASDAQ:PRCT) announced its quarterly earnings data on Wednesday. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.01), Zacks reports. PROCEPT BioRobotics had a negative return on equity of 27.16% and a negative net margin of 31.82%.The firm had revenue of $83.13 million during the quarter, compared to analysts’ expectations of $80.52 million. During the same quarter in the previous year, the business earned ($0.45) earnings per share. The company’s revenue for the quarter was up 20.1% compared to the same quarter last year.

Here are the key takeaways from PROCEPT BioRobotics’ conference call:

• PROCEPT reported a solid start to 2026 with $83.1 million in Q1 revenue (+20% YoY), ~12,200 U.S. procedures (+30% YoY), 49 HYDROS system sales, and record U.S. system ASPs (~$485,000) with handpiece ASPs around $3,500.
• The company hit a key margin milestone with a 65% gross margin in Q1 (in line with full?year guidance) and reiterated a path to positive adjusted EBITDA in Q4 2026.
• Management completed a commercial realignment into regional integrated teams and dedicated launch teams, which caused short?term disruption to procedure/handpiece trends in Q1 but is expected to drive stronger utilization and faster ramping in the back half of 2026.
• Clinical and regulatory momentum accelerated: the EAU upgraded Aquablation with a strong recommendation versus TURP, FDA cleared FirstAssist AI Gen2, HYDROS launched in the U.K., WATERFORT enrollment nears completion, and WATER IV primary endpoint is planned for AUA 2027.
• Operating expenses rose to $86.6 million, Q1 net loss widened to $31.6 million and adjusted EBITDA loss was $18.1 million; full?year adjusted EBITDA is still guided to a loss of $30M–$17M despite cash of $249 million supporting execution.

PROCEPT BioRobotics Stock Up 10.7%

Shares of PRCT stock opened at $24.04 on Friday. The stock has a 50 day moving average of $25.18 and a 200 day moving average of $29.52. The company has a current ratio of 6.85, a quick ratio of 5.77 and a debt-to-equity ratio of 0.14. The stock has a market cap of $1.37 billion, a P/E ratio of -13.21 and a beta of 0.94. PROCEPT BioRobotics has a twelve month low of $19.35 and a twelve month high of $66.85.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Leerink Partners reduced their price objective on PROCEPT BioRobotics from $55.00 to $30.00 and set an “outperform” rating for the company in a research note on Thursday, February 26th. Jefferies Financial Group cut PROCEPT BioRobotics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 26th. Weiss Ratings reissued a “sell (e+)” rating on shares of PROCEPT BioRobotics in a report on Tuesday, April 21st. Piper Sandler reissued an “overweight” rating and set a $35.00 target price (up from $28.00) on shares of PROCEPT BioRobotics in a report on Thursday. Finally, Wall Street Zen raised shares of PROCEPT BioRobotics from a “strong sell” rating to a “sell” rating in a report on Saturday, April 25th. Eight investment analysts have rated the stock with a Buy rating, four have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $41.45.

Insider Activity at PROCEPT BioRobotics

In related news, EVP Alaleh Nouri sold 6,892 shares of PROCEPT BioRobotics stock in a transaction that occurred on Friday, March 6th. The stock was sold at an average price of $23.70, for a total transaction of $163,340.40. Following the completion of the transaction, the executive vice president directly owned 114,264 shares in the company, valued at approximately $2,708,056.80. This trade represents a 5.69% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Kevin Waters sold 6,721 shares of PROCEPT BioRobotics stock in a transaction on Friday, March 6th. The shares were sold at an average price of $23.70, for a total transaction of $159,287.70. Following the completion of the transaction, the executive vice president directly owned 152,264 shares of the company’s stock, valued at $3,608,656.80. The trade was a 4.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders purchased 426,262 shares of company stock worth $10,483,091 and sold 23,229 shares worth $573,466. 6.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd increased its holdings in PROCEPT BioRobotics by 436.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 917 shares of the company’s stock valued at $29,000 after buying an additional 746 shares in the last quarter. US Bancorp DE increased its holdings in PROCEPT BioRobotics by 175.7% in the third quarter. US Bancorp DE now owns 1,693 shares of the company’s stock valued at $60,000 after buying an additional 1,079 shares in the last quarter. Kestra Advisory Services LLC purchased a new position in PROCEPT BioRobotics in the fourth quarter valued at $68,000. Lazard Asset Management LLC increased its position in shares of PROCEPT BioRobotics by 90.7% in the second quarter. Lazard Asset Management LLC now owns 1,703 shares of the company’s stock valued at $98,000 after buying an additional 810 shares in the last quarter. Finally, Osaic Holdings Inc. increased its position in shares of PROCEPT BioRobotics by 20.3% in the second quarter. Osaic Holdings Inc. now owns 2,001 shares of the company’s stock valued at $115,000 after buying an additional 337 shares in the last quarter. Hedge funds and other institutional investors own 89.46% of the company’s stock.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.